Water-insoluble drugs and their pharmacokinetic behaviors

Water-Insoluble Drug Formulation, Second Edition

Volumn , Issue , 2008, Pages 91-100

  Zhou, Honghui ^a  

^a Johnson and Johnson Pharmaceutical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84963644424     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (36)

1. Bates TR, Carrigan PJ. Apparent absorption kinetics of micronized griseofulvin after its oral administration on single- and multiple-dose regimens to rats as a corn oil-in-water emulsion and aqueous suspension. J Pharm Sci, 1975; 64: 1475-1481.
2. Bedford TA, Rowbotham DJ. Cisapride. Drug interactions of clinical significance. DrugSaf, 1996; 15: 167-175.
3. Bijanzadeh M, Mahmoudian M, Salehian P, Khazainia T, Eshghi L, Khosravy A. The bioavailability of griseofulvin from microsized and ultramicrosized tablets in nonfasting volunteers. Indian J Physiol Pharmacol, 1990; 34: 157-161.
4. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol, 2002; 97: 194-197.
5. Bonate PL, Floret S, Bentzen C. Population pharmacokinetics of APOMINE™: a meta-analysis in cancer patients and healthy males. Br J Clin Pharmacol, 2004; 58: 142-155.
6. Bradley C. Erythromycin as a gastrointestinal prokinetic agent. Intens Crit Care Nurs, 2001; 17: 117-119.
7. Cowan A, Earnest DL, Ligozio G, Rojavin MA. Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod. Eur J Pharmacol, 2005; 517: 127-131.
8. Cox SR, Harrington EL, Capponi VJ. Bioavailability studies with ciglitazone in beagles: II. Effect of propantheline bromide and metoclopramide HCL on bioavailability of a tablet. Biopharm Drug Dispos, 1985; 6: 81-90.
9. Degen L, Petrig C, Studer D, Schroller S, Beglinger C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil, 2005; 17: 821-826.
10. Gal J. New single-isomer compounds on the horizon. CNS Spectr, 2002; 7(Suppl 1): 45-54.
11. Garrigues TM, Martin U, Peris-Ribera JE, Prescott LF. Dose-dependent absorption and elimination of cefadroxil in man. Eur J Clin Pharmacol, 1991; 41: 179-183.
12. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., by Joel G. Hardman, Lee E. Limbird, Alfred Goodman, and Gilman (eds.), McGraw Hill, 2001.
13. Greiff JM, Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet, 1994; 27: 447-461.
14. Grevel J, Nüesch E, Abisch E, Kutz K. Pharmacokinetics of oral cyclosporine A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol, 1986; 31: 211-216.
15. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther, 1996; 60: 601-607.
16. Higaki K, Yamashita S, Amidon GL. Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn, 2001; 28: 109-128.
17. Holford NH, Ambros RJ, Stoeckel K. Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm, 1992; 20: 421-442.
18. Jamali F, Axelson JF. Influence of metoclopramide and propantheline on GI absorption of griseofulvin in rats. J Pharm Sci, 1977; 66: 1540-1543.
19. Jaruratanasirikul S, Sleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol, 1997; 52: 235-237.
20. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendine-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab, 2003; 88: 3082-3089.
21. Lange D, Pavao JH, Wu J, Klausner M. Effect of cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol, 1997; 37: 535-540.
22. Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Parti). Clin Pharmacokinet, 1990; 19: 11-31.
23. Mojaverian P, Ferguson PK, Vlasses PH, Rocci ML Jr, Oren A, Fix JA, Caldwell LJ, Gardner C. Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition. Gastroenterology, 1985; 89: 392-397.
24. Mojaverian P, Vlasses PH, Kellner PE, Rocci ML Jr. Effects of gender, posture, and age on gastric residence time of an indigestible solid: pharmaceutical considerations. Pharm Res, 1988; 5: 639-644.
25. Mojaverian P, Vlasses PH, Parker S, Warner C. Influence of single and multiple doses of oral ranitidine on the gastric transit of an indigestible capsule in humans. Clin Pharmacol Ther, 1990; 47: 382-388.
26. Nomeir AA, Mojaverian P, Kosoglou T, Affrime MB, Nezamic J, Rodwanski E, Lin CC, Cayen MN. Influence of food on the oral bioavailability of loratadine and psuedoephedrine from extended-release tablets in healthy volunteers. J Clin Pharmacol, 1996; 36: 923-930.
27. Ogunbona FA, Smith IF, Olawoye OS. Fat contents of meals and bioavailability of griseofulvin in man. J Pharm Pharmacol, 1985; 37: 283-284.
28. Teorell T. Kinetics of distribution of substances administered to the body. Arch Intern Pharmacodyn, 1937; 57: 205-240.
29. Toothaker RD, Welling PG. The effect of food on drug bioavailability. Annu Rev Pharmacol Toxicol, 1980; 20: 173-199.
30. Van de Velde VJ, Van Peer AP, Heykants JJ, Woestenborghs RJ, Van Rooy P, De Beule KL, Cauwenbergh GF. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy, 1996; 16: 424-428.
31. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation, 1987; 43: 211-213.
32. Welling PG. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm, 1977; 5: 291-334.
33. Welling PG, Tse FL. Factors contributing to variability in drug pharmacokinetics. I. Absorption. J Clin Hosp Pharm, 1984; 9: 163-179.
34. Wood M. Pharmacokinetic drug interactions in anesthetic practice. Clin Pharmacokinet, 1991; 21: 285-307.
35. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol, 2003; 43: 211-227.
36. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol, 1994; 46: 147-150.